Integrated extracellular microRNA profiling for ovarian cancer screening
Percentage of samples :
Cancer : 115 / Control : 2759
Data Processing :
The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.
Data Summary :
A serum miRNA combination could be a powerful classifier for the detEsophageal Cancertion of patients with ovarian cancer.
Overall design :
Serum microRNA profiles of 4046 woman samples, which consist of 333 of ovarian cancers, 66 of borderline ovarian tumors, 29 of benign ovarian diseases, 2759 of non-cancer controls, and 859 of the other solid cancers.
Citation(s) :
Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun 2018 Oct 17;9(1):4319. PMID: 30333487
Extraction Protocol :
Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
Extraction Molecule :
total RNA
Lable :
Cy3
Label Protocol :
miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.
Hybridization Protocol :
Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.
Scan Protocol :
3D-Gene Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).
